Filing Details

Accession Number:
0001181431-10-042350
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2010-08-18 13:00:00
Reporting Period:
2010-08-06
Filing Date:
2010-08-18
Accepted Time:
2010-08-18 13:40:49
Original Submission Date:
2010-08-10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1356857 Trius Therapeutics Inc TSRX Pharmaceutical Preparations (2834) 201320630
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1245624 James Healy 140 Geary Street, 10Th Floor
San Francisco CA 94108
No No Yes No
1362314 Eric Buatois 140 Geary Street, 10Th Floor
San Francisco CA 94108
No No Yes No
1380734 P L Vii Partners Venture Sofinnova 140 Geary Street
10Th Floor
San Francisco CA 94108
No No Yes No
1421501 Sofinnova Management Vii, L.l.c. 140 Geary Street, 10Th Floor
San Francisco CA 94108
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2010-08-06 1,892,177 $0.00 1,892,177 No 4 C Direct
Common Stock Acquisiton 2010-08-06 893,395 $4.38 2,785,572 No 4 C Direct
Common Stock Acquisiton 2010-08-06 830,000 $5.00 3,615,572 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A-2 Convertible Preferred Stock Disposition 2010-08-06 10,909,092 $0.00 10,909,092 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2010-08-06 5,363,636 $0.00 5,363,636 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. Upon the closing of the Issuer's initial public offering, each 8.6 shares of the Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into one share of Common Stock, and had no expiration date.
  2. Shares are held by Sofinnova Venture Partners VII, L.P. ("SV VII"). Sofinnova Management VII, L.L.C ("SV VII LLC") is the general partner of SV VII, and Michael F. Powell, a director of the issuer, James I. Healy and Eric P. Buatois, the managing general partners of SV VII, LLC, may be deemed to share voting and dispositive power over the shares held by SV VII. Such persons disclaim beneficial ownership of shares held by SV VII except to the extent of any pecuniary interest therein.
  3. The Common Stock was acquired upon conversion of a Secured Convertible Promissory Note exempt from the definition of a derivative security and whose conversion ratio did not become fixed until automatic conversion at the time of the closing of the Issuer's initial public offering.
  4. The shares were purchased in the Issuer's initial public offering.
  5. Transaction lines included in amendment to gain access to the filing system. Reporting Persons on Exhibit 99.1 were inadvertently omitted from the previous filing, and this report is being amended to reflect a joint/group filing.